Welcome to our dedicated page for ARS Pharms news (Ticker: SPRY), a resource for investors and traders seeking the latest updates and insights on ARS Pharms stock.
ARS Pharmaceuticals, Inc. develops and commercializes neffy, an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. The company’s news commonly covers U.S. commercialization, product labeling, international approvals and licensing relationships for neffy, which is marketed as EURneffy in the European Union and the United Kingdom and under a separate trade name in China.
Recurring updates also include quarterly and annual financial results, clinical and scientific presentations on intranasal epinephrine, school-access programs, manufacturing and supply responsibilities for partners, and investor conference activity. The company’s allergy-treatment focus makes regulatory decisions, product access, clinical data and commercial launch progress central themes in its public announcements.
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results and business highlights.
Management will also participate in investor conferences on Feb 25, Mar 11, and Mar 22, 2026; webcasts and replay access are available via the company’s Events & Presentations page for 30 days.
ARS Pharmaceuticals (Nasdaq: SPRY) will present clinical and economic data on neffy® (epinephrine nasal spray) at the AAAAI Annual Scientific Meeting, Feb 27–Mar 2, 2026. Five posters, one HCP case report and two ALK late-breakers cover pharmacokinetics, usability, preference and health‑economic analyses.
Company said neffy 2 mg shows similar exposure to 0.5 mg intramuscular injection, longer shelf life versus autoinjectors, and pharmacoeconomic models indicate increased value when accounting for needle aversion.
ARS Pharmaceuticals (Nasdaq: SPRY) announced that the EMA CHMP has adopted a positive opinion recommending expansion of EURneffy marketing authorization to include a 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children weighing ≥15 kg to <30 kg.
Following European Commission approval, ALK-Abelló will distribute EURneffy across EU member states, Iceland, Liechtenstein and Norway; this complements the August 2024 EC approval of EURneffy 2 mg for patients ≥30 kg and recent regulatory activity in the U.S., Canada (anticipated), Japan, China and Australia.
ARS Pharmaceuticals (Nasdaq: SPRY) announced that California K-12 schools are now eligible for the neffyinSchools program, which provides free needle-free neffy® epinephrine nasal spray for emergency use.
The program, launched in January 2025, now spans 24 states with more than 8,000 participating schools; ARS Pharma has donated nearly 45,000 doses to date. Eligible public and private K-12 schools can request two cartons (four single-use doses) of neffy 1 mg and 2 mg at no cost and may receive replacements after use or expiration.
ARS Pharmaceuticals (Nasdaq: SPRY) announced NMPA approval in China for neffy 2 mg (epinephrine nasal spray) for emergency treatment of Type 1 allergic reactions in adults and children ≥30 kg, marking the first community-use epinephrine product approved in China. ARS licensed commercialization rights to Pediatrix Therapeutics (trade name 优敏速®) and expects availability in spring 2026. ARS will receive a $4M final regulatory milestone, be eligible for up to $80M in sales milestones, and royalties in the low double digits; ARS will manufacture and supply product to Pediatrix at cost of goods. ARS and partners also have approvals/launches in Australia, New Zealand (expected), U.S., and Europe.
ARS Pharmaceuticals (Nasdaq: SPRY) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, December 2-4, 2025.
Company executives Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, will take part in a fireside chat on Wednesday, December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. Management will hold one-on-one investor meetings. A live webcast of the fireside chat will be available on the company website and a replay will be archived for 90 days.
ARS Pharmaceuticals (Nasdaq: SPRY) reported third quarter 2025 results and commercial progress for neffy® (epinephrine nasal spray). Q3 revenue was $32.5M, including $31.3M U.S. net product revenue; net loss was $51.2M (−$0.52/share). Cash, cash equivalents and short-term investments totaled $288.2M as of September 30, 2025, after a $100M draw on a $250M term loan facility; shares outstanding were 98,844,178. Commercial milestones: consumer awareness rose from ~20% to 56%, >18,000 HCPs prescribed neffy (an 86% increase), >6,500 schools enrolled, and real-world data (n=680) showed ~90% effective single-dose treatment rates.
ARS Pharma (Nasdaq: SPRY) launched Get neffy on Us on November 4, 2025, an integrated commercial program to expand access to neffy (epinephrine nasal spray).
Key features: a free virtual prescriber visit taking 5–10 minutes, potential $0 co-pay for eligible commercially insured patients, and delivery to a pharmacy or home within 3–5 days. The company cites ~40 million people with severe allergies and survey interest of >70% in virtual prescribing. The program complements neffyInSchools, which has provided neffy to >6,600 schools across >20 states. More information is available at www.getneffy.com or 1-877-MY-NEFFY.
ARS Pharma (Nasdaq: SPRY) will present one late-breaking oral and six poster presentations featuring real-world data on neffy® (epinephrine nasal spray) at the 2025 ACAAI Annual Scientific Meeting in Orlando, Nov 6–10, 2025.
The late-breaking oral presentation, “Real World Data on the Effectiveness of Epinephrine Nasal Spray in Clinical Practice – Update,” is scheduled for Nov 8, 2025 at 5:23 PM ET. Six poster sessions and five clinician case reports will report real-world use, safety, and administration topics. ARS will host onsite activities and exhibit at booth #400.
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Monday, November 10, 2025 at 5:30 a.m. PT / 8:30 a.m. ET to discuss third quarter 2025 financial results and business highlights. Dial-in details are available by registering for the event.
Investors can access the live webcast and slides on the company’s Investors & Media > Events & Presentations page. A replay of the webcast will be available for 30 days after the event.